Botulinum Toxin-A for the Treatment of Voiding Dysfunction Our Initial Experience英文文献资料.docVIP

Open Journal of Urology, 2012, 2, 67-71 67 /10.4236/oju.2012.22011 Published Online May 2012 (http://www.SciRP.org/journal/oju) Botulinum Toxin-A for the Treatment of Voiding Dysfunction: Our Initial Experience Sinharib Citgez, Bulent Onal, Fetullah Gevher, Cagatay Dogan, Omer Kurt, Oktay Demirkesen, Bulent Cetinel * Department of Urology, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey * Email: bulent.cetinel@ Received March 14, 2012; revised March 26, 2012; accepted April 10, 2012 ABSTRACT Objective: Evaluation of Botulinum Toxin-A (BTX-A) as an alternative treatment option in patients whom previous treatments were failed. Methods: Between March 2005 and September 2006, a total 19 patients; 16 patients with overactive bladder (5 neurologic, 11 idiopathic), 2 with nocturnal enuresis, 1 with interstitial cystitis, intravesical BTX-A injection was applied. Except one patient, 18 patients with a median age 46 (20 - 80) were registered to the stu- dy. Patients were examined at postoperative 3 weeks and 6 months with ICIQ-SF (International Consultation on Incon- tinence Questionnaire-Short Form) and satisfaction forms used in our clinic. Results: The median follow-up time was 16 months (6 - 18). When evaluated according to diagnosis, symptoms were improved 100% in neurologic overactive bladder (5/5), 80% in idiopathic overactivity (8/10), 50% in nocturnal enuresis (1/2). In one patient with interstitial cystitis there was no improvement. Median efficiency time of BTX-A treatment was 6 months (1 - 17). At 3 weeks and 6 months after the treatment, ICIQ-SF score was decreased to 3.6 and 7.5 respectively from preoperative level of 18.7. Quality of life scores at preoperative, 3 week and 6 months were 9.7, 2.7 and 4.3 respectively. Except 3 patients with overactive neurologic bladder because of spinal cord injury, symptoms of patients with pollacuria and nocturia decreas